U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H7O6P.2Na
Molecular Weight 216.0374
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM 2-GLYCEROPHOSPHATE

SMILES

[Na+].[Na+].OCC(CO)OP([O-])([O-])=O

InChI

InChIKey=AVPCPPOOQICIRJ-UHFFFAOYSA-L
InChI=1S/C3H9O6P.2Na/c4-1-3(2-5)9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2

HIDE SMILES / InChI
Sodium glycerol 2-phosphate (Disodium beta-glycerophosphate) is used for the preparation of thermo-sensitive chitosan hydrogen as a scaffold to construct tissue engineered injectable nucleus pulposus (NP). Since Sodium glycerol 2-phosphate (6 g/day) reduced the lithogenic index of bile in human subjects with cholesterol gallstones in a short-term study and facilitated dissolution of cholesterol gallstones in mice, Sodium glycerol 2-phosphate may have potential to help dissolve cholesterol gallstones in man. Sodium glycerol 2-phosphate is an alkaline phosphate inhibitor. Sodium β-glycerophosphate pentahydrate is used as a phosphatase inhibitor. It promotes bone matrix mineralization while delivering to osteoblasts by providing a source of phosphate ions. It is used in the development of hydrogels and scaffolds, which finds applications in tissue engineering and cell growth. It is used as an additive in isolation mediums by providing phosphate ions to isolate. It is utilized to promote mineralization in vitro by modulating bone cell metabolic activity.

Originator

Sources: DOI: 10.1002/hlca.6602801220

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Glycophos

Approved Use

Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of oral administration of 'essential' phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis.
1979
Pericytes derived from the retinal microvasculature undergo calcification in vitro.
1990 Nov
Mechanism of action of beta-glycerophosphate on bone cell mineralization.
1992 Oct
Biomimetic apatite coatings on micro-arc oxidized titania.
2004 Aug
Bone regeneration by grafting of cultured human bone.
2004 May-Jun
Enhancing effect of daidzein on the differentiation and mineralization in mouse osteoblast-like MC3T3-E1 cells.
2006 Aug
Antibacterial properties of Ag (or Pt)-containing calcium phosphate coatings formed by micro-arc oxidation.
2009 Jan
[Comparison study on injectable tissue engineered nucleus pulposus constructed by different cells and chitosan hydrogel].
2010 Jul
Taurine suppresses osteoblastic differentiation of aortic valve interstitial cells induced by beta-glycerophosphate disodium, dexamethasone and ascorbic acid via the ERK pathway.
2012 Oct
Generation of osteogenic construct using periosteal-derived osteoblasts and polydioxanone/pluronic F127 scaffold with periosteal-derived CD146 positive endothelial-like cells.
2013 Apr
The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway.
2017
Bone regeneration with osteogenic matrix cell sheet and tricalcium phosphate: An experimental study in sheep.
2017 Oct 18
Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis.
2018 Aug
In vitro and in vivo acute response towards injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofiber hydrogel.
2018 Jan 15
Patents

Sample Use Guides

Dose Adults: The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 mL of GLYCOPHOS (Sodium glycerophosphate pentahydrate) added to the infusion solution or to the admixture for which compatibility has been proved. Children, Infants and Neonates: The recommended dosage is individual. The recommended dose for children, infants and neonates is 1.0-1.5 mmol/kg body weight/day. Method of administration Intravenous Infusion. GLYCOPHOS must not be given undiluted. The infusion time should not be less than 8 hours.
Route of Administration: Intravenous
In Vitro Use Guide
Medium supplementation with beta-GP (Sodium 2-glycerophosphate) should not exceed 2 mM.
Name Type Language
SODIUM 2-GLYCEROPHOSPHATE
Common Name English
1,2,3-PROPANETRIOL, 2-(DIHYDROGEN PHOSPHATE), SODIUM SALT (1:2)
Common Name English
1,2,3-PROPANETRIOL, 2-(DIHYDROGEN PHOSPHATE), DISODIUM SALT
Common Name English
.BETA.-GLYCEROPHOSPHATE DISODIUM
Common Name English
.BETA.-PHOSPHOGLYCEROL SODIUM
Common Name English
Code System Code Type Description
CAS
819-83-0
Created by admin on Fri Dec 15 15:53:31 GMT 2023 , Edited by admin on Fri Dec 15 15:53:31 GMT 2023
PRIMARY
PUBCHEM
4531952
Created by admin on Fri Dec 15 15:53:31 GMT 2023 , Edited by admin on Fri Dec 15 15:53:31 GMT 2023
PRIMARY
ECHA (EC/EINECS)
212-464-3
Created by admin on Fri Dec 15 15:53:31 GMT 2023 , Edited by admin on Fri Dec 15 15:53:31 GMT 2023
PRIMARY
FDA UNII
518FQS69A0
Created by admin on Fri Dec 15 15:53:31 GMT 2023 , Edited by admin on Fri Dec 15 15:53:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID301002290
Created by admin on Fri Dec 15 15:53:31 GMT 2023 , Edited by admin on Fri Dec 15 15:53:31 GMT 2023
PRIMARY